• Content
          • Newsroom
            • Press releases
Ukraine Response

Our top priority is the health and safety of our colleagues and we continue to monitor their circumstances and provide targeted support for urgent needs.

Consistent with our Mission, the company, through direct donation and matching gifts, and our colleagues are donating more than $1.25 million towards relief efforts for Ukraine through organizations including the International Committee for the Red Cross, International Rescue Committee, and Save the Children.

Given the ongoing conflict, we have stopped sales and manufacturing operations in Russia and Belarus. We are prioritizing critical healthcare-related deliveries and operations in these countries to limit any potential patient impact. In addition, our clinical trial service delivery in Ukraine has been temporarily halted and will resume once safe to do so.

We will continue to monitor the situation and adjust accordingly.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

SOURCE Thermo Fisher Scientific

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Thermo Fisher Scientific Inc. published this content on 10 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 March 2022 16:49:08 UTC.